HomeBCRX • NASDAQ
add
BioCryst Pharmaceuticals Inc
Nakaraang pagsara
$8.22
Sakop ng taon
$6.00 - $11.31
Market cap
2.06B USD
Average na Volume
4.60M
P/E ratio
6.81
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 406.56M | 209.09% |
Gastos sa pagpapatakbo | 93.74M | 16.53% |
Net na kita | 245.84M | 1,017.50% |
Net profit margin | 60.47 | 396.86% |
Kita sa bawat share | — | — |
EBITDA | 267.55M | 11,033.92% |
Aktuwal na % ng binabayarang buwis | 0.88% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 274.75M | -14.37% |
Kabuuang asset | 514.16M | 4.84% |
Kabuuang sagutin | 633.31M | -34.46% |
Kabuuang equity | -119.15M | — |
Natitirang share | 250.80M | — |
Presyo para makapag-book | -14.68 | — |
Return on assets | 138.82% | — |
Return on capital | 204.09% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 245.84M | 1,017.50% |
Cash mula sa mga operasyon | 291.96M | 5,700.61% |
Cash mula sa pag-invest | -83.49M | -569.11% |
Cash mula sa financing | -217.96M | -5,320.54% |
Net change in cash | 5.28M | -27.26% |
Malayang cash flow | 200.12M | 2,602.96% |
Tungkol
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Itinatag
1986
Headquarters
Website
Mga Empleyado
435
